Recent Quotes
My Watchlist
Indicators
Local Stocks
WallStreetSelect 114
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Replimune Group Inc (NQ: REPL )

12.02 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EST, Nov 5, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 332,931
Open 12.08
Bid (Size) 11.42 (1)
Ask (Size) 12.63 (1)
Prev. Close 12.02
Today's Range 11.72 - 12.33
52wk Range 4.920 - 14.72
Shares Outstanding 46,772,263
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Replimune to Present at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)
From Replimune Group Inc
Via GlobeNewswire
REPL Stock Earnings: Replimune Group Beats EPS for Q1 2025
REPL stock results show that Replimune Group beat analyst estimates for earnings per share the first quarter of 2025. 
Via InvestorPlace

Performance

YTD
+38.64%
+38.64%
1 Month
+6.09%
+6.09%
3 Month
+23.66%
+23.66%
6 Month
+71.47%
+71.47%
1 Year
-6.60%
-6.60%

More News

Read More
Vail Resorts Posts Downbeat Q3 Results, Joins Concrete Pumping, DocuSign And Other Big Stocks Moving Lower In Friday's Pre-Market Session
Via Benzinga
S&P 500 Edges Lower; J. M. Smucker Shares Surge Following Earnings Beat
Via Benzinga
Topics Stocks
Exposures US Equities
12 Health Care Stocks Moving In Thursday's Intraday Session
Via Benzinga
Replimune Group: Q3 Earnings Insights
Via Benzinga
Barclays Maintains Overweight Rating for Replimune Group: Here's What You Need To Know
Via Benzinga
Why G-III Apparel Shares Are Trading Lower By 13%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Via Benzinga
Crude Oil Jumps 2%; Lululemon Posts Upbeat Earnings
Via Benzinga
Exposures Fossil Fuels
Why Is Mid-Cap Cancer-Focused Replimune Stock Trading Higher On Thursday?
Via Benzinga
The Latest Analyst Ratings for Replimune Group
Via Benzinga
Analyst Ratings for Replimune Group
Via Benzinga
J.M. SmuckerPosts Upbeat Earnings, Joins Toro Company, United Natural Foods, Semtech And Other Big Stocks Moving Higher On Thursday
Via Benzinga
REPL Stock Earnings: Replimune Group Misses EPS for Q4 2024
Via InvestorPlace
Crude Oil Moves Lower; AutoZone Profit Tops Views
Via Benzinga
Topics Stocks
Exposures Fossil Fuels US Equities
Why Daktronics Shares Are Trading Lower By Over 10%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Intraday Session
Via Benzinga
Dow Falls 100 Points; ISM Services PMI Increases In November
Via Benzinga
Topics Stocks
Exposures US Equities
Why Is Replimune (REPL) Stock Down 48% Today?
Via InvestorPlace
US Stocks Down; JM Smucker Posts Upbeat Earnings
Via Benzinga
Topics Stocks
Exposures US Equities
What's Going On With Cancer-Focused Replimune Stock Today?
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Via Benzinga
8 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
Replimune and Incyte Enter into Clinical Trial Collaboration and Supply Agreement to Evaluate RP1 and INCB99280 in Patients with Cutaneous Squamous Cell Carcinoma
From Incyte
Via Business Wire
Stock Market Rally Broadens Out; Apple Unveils Vision Pro, SEC Sues Binance, Coinbase: Weekly Review
Via Investor's Business Daily
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.